# PURE-01 (NCT02736266)

> Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02736266
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Conditions: Urothelial Bladder Carcinoma
- Interventions: Pembrolizumab (MK-3475)
- Enrollment: 174
- Primary outcome: Pathologic complete response

## Commentary we found

- X threads: 58
- Podcasts: 6
- YouTube: 4
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=pure-01-nct02736266

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02736266", "email": "<work email>"}; the inbox owner confirms by the emailed link.